JPRN-jRCTs031210339招募中4 期
Effect of Tofogliflozin on Urine Albumin-to-Creatinine Ratio Compared to Metformin Hydrochloride in Diabetic Kidney Disease - TRUTH-DKD Study
Kuwahara Koichiro0 个研究点目标入组 120 人开始时间: 2021年9月22日最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable(—)
- 性别
- All
入选标准
- •Patients who meet all of the following selection criteria are included.
- •1. Type 2 diabetic patients
- •2. Patients aged 20 years or older at the time of obtaining consent
- •3. Patients with HbA1c 6.5 or more and 9.0% or less within 13 weeks before obtaining consent (evaluated by test values after 4 weeks or more without taking SGLT2 inhibitor/metformin)
- •4. Patients who have been judged by their doctor to need a diabetic drug when they are first seen, or who have already taken a diabetic drug and have decided that it is necessary to add one diabetic drug.
- •5. Patients who have been receiving RAS inhibitors (ARB, ARNI, ACE inhibitors, direct renin inhibitors) for 4 weeks or longer
- •6.Patients with eGFR of 30 or more (mL/ min/1.73m2) within 13 weeks before obtaining consent (evaluated by test values after 4 weeks or more without taking SGLT2 inhibitor/metformin)
- •7. Patients with urinary albumin/creatinine ratio (UACR) of 30 or more and less than 2000 (mg /gCr) (4 weeks or more without taking SGLT2 inhibitor/metformin) within 13 weeks before obtaining consent Evaluate by inspection value)
- •8. Patients for whom written consent was obtained based on the patient's free will after receiving sufficient explanation for participation in this study
排除标准
- •1. Patients receiving treatment with SGLT2 inhibitor or metformin within 13 weeks before obtaining consent
- •2. Dialysis patient
- •3. Patients with a history of severe hypoglycemia
- •4. Patients with hypersensitivity to SGLT2 inhibitor or metformin
- •5. Pregnant women, lactating patients, and patients who wish to raise children
- •6. Patients with BMI of 35 kg / m2 or more based on the latest measured values within 13 weeks before obtaining consent
- •7. Patients who are contraindicated for the study drug
- •8. Other patients who the attending physician deems inappropriate as a subject
研究者
相似试验
已完成
4 期
EUROBEAT StudyType 2 diabetes mellitusJPRN-jRCTs051200147Makino Hisashi80
已完成
不适用
Effect of canagliflozin on urinary albumin excretion in type 2 diabetic patients with microalbuminuria (pilot study)Type 2 diabetic patients with microalbuminuriaJPRN-UMIN000023959akakinen clinic Medical Corporation Kensei-kai20
已完成
不适用
Study of the effect of tofogliflozin on glucose and lipid metabolism abnormality after the test meal loading.JPRN-UMIN000015778Kanazawa Medical University10
已完成
1 期
Effect of empagliflozin/linagliptin on albuminuria and urinary liver-type free fatty acid binding protein in type 2 diabetic patients with chronic kidney disease: A randomized controlled trialT2DM and CKD patients with albuminuriaTCTR20210317005/A48
招募中
2 期
Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)T2DM (Type 2 Diabetes Mellitus)MetforminSGLT2-InhibitorsNCT05469659Shinshu University120
